ZUMA-1: safety and efficacy of axicabtagene in refractory non-Hodgkin lymphoma patients
0 Views
administrator
07/09/23
Sattva Neelapu, MD, University of Texas MD Anderson Cancer Center, Houston, TX, updates us on the ZUMA-1 study (NCT02348216), investigating the safety and efficacy of axicabtagene ciloleucel, CAR-T cell therapy, in relapsed, aggressive follicular lymphoma and marginal zone lymphoma patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
-
Category
Show more
Facebook Comments
No comments found